Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Bloomberg Markets

Compass Pathways CEO on Trump's Order to Expand Psychedelics Research

Compass Pathways CEO on Trump's Order to Expand Psychedelics Research
ShareXFacebook

Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its

B

Source

Bloomberg Markets

Read full article at Bloomberg Markets

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement